While genetic testing for variants linked to non response is not common, it represents the next step in helping ensure patients are given therapies that work better for them
Reduced L-glutathione (GSH) is the body's master intracellular antioxidant, neutralizing reactive oxygen species (ROS) generated during mitochondrial fat oxidation
In preclinical studies, BPC-157 demonstrated an exceptionally wide therapeutic window with no observed toxicity even at high doses. Sikiric et al., Current Pharmaceutical Design Long-Term Safety As of now, long-term human safety data is lacking
Thirteen percent of survey respondents reported trying a GLP-1 medication, while 37% said someone close to them had
Moreover, since at the time of diagnosis, 50% of patients presents metastases, 29% local/regional spread, and only 3% pancreatic carcinoma in situ, less than 15% of patients are eligible for surgical resection, compromising research efforts for inadequate number of available human samples [9,10,11, 13, 14]